Strategies of immunoescape in Epstein-Barr virus persistence and pathogenesis

Seminars in Virology

Volumn 7, Issue 1, 1996, Pages 75-82

  De Campos Lima, Pedro Otaviode ^a   Levitskaya, Jelena ^a   Frisan, Teresa ^a   Masucci, Maria G ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

CTL; EBV; Escape mutants

Indexed keywords

VIRUS ANTIGEN;

ANTIGEN RECOGNITION; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; HUMAN; IMMUNOCOMPETENCE; NONHUMAN; PERSISTENT INFECTION; REVIEW; VIRUS CARCINOGENESIS; VIRUS CELL TRANSFORMATION; VIRUS IMMUNITY; VIRUS INFECTION; VIRUS LATENCY;

HUMAN HERPESVIRUS 4;

EID: 0029977982     PISSN: 10445773     EISSN: None     Source Type: Journal    
DOI: 10.1006/smvy.1996.0009     Document Type: Review

References (45)

1. Hanto DW, Frizzera G, Gajl-Peczalska KJ, Simmons RL (1985) Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation 39:461-472
2. Epstein MA, Achong BG, Barr YM (1964) Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet i:702-703
3. Pallesen G, Hamilton-Dutoit SJ, Zhou X (1993) The association of Epstein-Barr virus (EBV) with T cell lymphoproliferations and Hodgkin's disease: Two new developments in the EBV field. Adv Cancer Res 62:180-239
4. + malignant lymphomas. Crit Rev Oncogenesis 4:191-239
5. Wolf H, Zur Hausen H, Becker V (1973) EB-viral genomes in epithelial nasopharyngeal carcinoma cells. Nature 244:245-247
6. Leyvraz S, Henle W, Chahinian AP, Perlman C, Klein G, Gordon RE, Rosenblum M, Holland JF (1985) Association of Epstein-Barr virus with thymic carcinoma. N Engl J Med 312:1296-1299
7. Imai S, Koizumi S, Sugiura M, Tokonuga M, Umeura Y, Yamamoto N, Tanaka S, Sato E, Osato T (1994) Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection proteins. Proc Natl Acad Sci USA 91:9131-9135
8. McClain KL, Leach CT, Jenson HB, Joshi VV, Pollock BH, Parmley RT, DiCarlo FJ, Chadwick EG, Murphy SB (1995) Association of Epstein-Barr virus with leiomyosarcomas in young people with AIDS. N Engl J Med 332:12-18
9. Lee ES, Locker J, Nalesnik M, Reyes J, Jaffe R, Alashari M, Nour B, Tzakis A, Dickman PS (1995) The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med 332:19-25
10. Kieff E, Liebowitz D (1990) Epstein-Barr virus and its replication (Fields B, Knipe D, eds) Virology, 2nd Edition, pp 1889-1920. Raven Press, New York
11. Strang G, Rickinson AB (1987) Multiple HLA class I-dependent cytotoxicities constitute the non-HLA-restricted response in infectious mononucleosis. Eur J Immunol 17:1007-1013
12. Moss D, Rickinson A, Pope J (1978) Long-term T-cell mediated immunityto Epstein-Barr virus in man: III. Activation of cytotoxic T cells in virus infected leukocyte cultures. Int J Cancer 23:618-625
13. Rickinson AB, Moss DJ, Allen DJ, Wallace LE, Rowe M, Epstein MA (1981) Reactivation of Epstein-Barr virus-specific cytotoxic T cells by in vitro stimulation with the autologous lymphoblastoid cell line. Int J Cancer 27:593-601
14. Masucci MG, Ernberg I (1994) Epstein-Barr virus: Adaptation to a life within the immune system. Trends Microbiol 2:125-130
15. de Campos-Lima PO, Levitsky V, Brooks J, Lee SP, Hu LF, Rickinson AB, Masucci MG (1994) T cell responses and virus evolution: Epstein-Barr virus isolates from highly HLAA11-positive populations carry mutations selectively involving anchor residues of All-restricted CTL epitopes. J Exp Med 179:1297-1305
16. Hill AB, Lee SP, Hauram JS, Murray N, Yao Q-Y, Rowe M, Signoret N, Rickinson AB, McMichael AL (1995) Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV) nuclear antigens fail to lyse the EBV-transformed B lymphoblastoid cell lines against which they were raised. J Exp Med 181:2221-2228
17. Gratama JW, Oosterveer MAP, Zwaan FE, Lepoutre J, Klein G, Ernberg I (1988) Eradication of Epstein-Barr virus by allegeneic bone marrow transplantation: implications for sites of viral latency. Proc Natl Acad Sci USA 85:8693-8696
18. Miyashita EM, Yang B, Lam KM, Crawford DH, Thorley-Lawson DA(1995) A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell 80:593-601
19. Chen F, Zou JZ, di Rienzo L, Wimberg G, Hu LF, Klein E, Klein G, Ernberg I (1995) A subpopulation of latently EBV infected normal B-cells resembles Burkitt lymphoma (BL) in expressing EBNA1 but not EBNA2 or LMP1. J Virol 1995:3752-3758
20. Tierney RJ, Steven N, Young LS, Rickinson AB (1994) Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol 68:7374-7385
21. Trivedi P, Masucci M, Wimberg G, Klein G (1991) The Epstein-Barr virus encoded membrane protein LMP but not the nuclear antigen EBNA-1 induces rejection of transfected murine mammary carcinoma lines. Int J Cancer 48:794-800
22. Dillner J, Sternås L, Kallin B, Alexander H, Ehlin-Henriksson B, Jörnvall H, Klein G, Lerner R (1984) Antibodies against a synthetic peptide identify the Epstein-Barr virus-determined nuclear antigen. Proc Natl Acad Sci 81:4652-4656
23. Stuber G, Dillner J, Mordow S, Wolf H, Szekely L, Klein G, Klein E (1995) JLA-A0201 and HLAB27 binding peptides in the EBV encoded EBNA-1, EBNA-2 and BZLF-1 detected in the MHC class I stabilization assay. Low proportion of binding motifs for several HLA Class I alleles in EBNA-1. Int Immunol 7:653-663
24. Levitskaya J, Coram M, Levitsky V, Imreh S, Stegerwald-Mullen PM, Klein G, Kurilla MG, Masucci MG (1995) Inhibition of antigen processing by the internal repeat region of the Epstein-Barr Virus nuclear antigen-1. Nature 375:685-688
25. Hill A, Jugovic P, York I, Russ G, Bennik J, Yewdell J, Ploegh H, Johnson D (1995) Herpes simplex virus turns off the TAP to evade host immunity. Nature 375:411-415
26. Früh K, Ahn K, Djabellah H, Pempe P, van Endert PM, Tampe R, Petersson PA, Yan Y (1995) A viral inhibitor of peptide transporters for antigen presentation. Nature 375:415-419
27. Beersma MFC, Bijlmakers MJE, Ploegh HL (1993) Human cytomegalovirus down-regulates HLA class I expression by reducing the stability of class I H chains. J Immunol 151:4455-4464
28. Moore K, Vieira P, Fiorentino D, Trounstine M, Khan T, Mosmann T (1990) Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science 248:1230-1234
29. de Waal-Malefyt R, Haanen J, Spits H, Roncarolo MG, Te Velde A, Figdor C, Johnson K, Kastelein R, Yssel H, de Vries JE (1991) Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen presenting capacity of monocytes via down-regulation of class II major histocompatibility complex expression. J Exp Med 174:915-924
30. Nakagomi H, Dolcetti R, Bejarano MT, Pisa P, Kiessling R, Masucci MG (1994) The Epstein-Barr virus latent membrane protein-1 (LMP1) induces production of interleukin-10 in Burkitt lymphoma lines. Int J Cancer 57:240-244
31. Bejarano MT, de Waal Malefyt R, Abrams JS, Bigler M, Bacchetta R, de Vires J, Roncarolo MG (1992) Interleukin 10 inhibits allogeneic proliferative and cytotoxic T cell responses generated in primary mixed lymphocyte culture. Int Immunol 4:1389-1397
32. Matsuda M, Slazar F, Petersson M, Masucci G, Hansson J, Pisa P, Zhang QJ, Masucci MG, Kiessling R (1994) Interleukin-10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 180:2371-2376
33. + population. Science 260:98-100
34. Starlz TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, Rosenthal JT, Hakala TR, Shaw BW, Hardesty RL, Atchinson RW, Jaffe R, Bahnson HT (1984) Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-A-steroid therapy. Lancet 1:583-587
35. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, Brenner MK and Heslop HE (1995) Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus related lymphoproliferations. Lancet 345:9-13
36. Papadopulos EB, Ladany M and Emanuel D (1994) Infusion of donor leukocytes to treat Epstein-Barr virus associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 330:1185-1191
37. Magrath I (1990) The pathogenesis of Burkitt's lymphoma. Adv Cancer Res 55:133-270
38. Whittle HC, Brown J, Marsh K, Greenwood BM, Seidelin P, Tighe H, Wedderburn L (1984) T-cell control of Epstein-Barr virus-infected B cells is lost during P. falciparum malaria. Nature 312:449-450
39. Cuomo L, Trivedi P, Wang F, Wimberg G, Klein G, Masucci M (1990) Expression of the Epstein-Barr virus (EBV)-encoded membrane antigen LMP increases the stimulatory capacity of EBV negative B lymphoma lines in allogeneic mixed lymphocyte cultures. Eur J Immunol 20:2293-2299
40. Wang F, Gregory CD, Sample C, Rowe M, Liebowitz D, Murray R, Rickinson AB, Kieff E (1990) Epstein-Barr virus latent membrane protein (LMP-1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA2 and LMP-1 cooperatively induce CD23. J Virol 64:2309-2318
41. Rowe M, Khanna R, Jacob CA, Argaet V, Kelly A, Pwis S, Belich M, Croom-Carter D, Lee S, Borrwos SR, Trawsdale J, Moss DJ, Rickinson AB (1995) Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate upregulation of peptide transporters and HLA-class I antigen expression. Eur J Immunol 25:1374-1384
42. de Campos-Lima PO, Torsteinsdottir S, Klein G, Solitzeanu D, Masucci MG (1993) Antigen processing and presentation by EBV carrying cell lines. Phenotype dependence and influence of the EBV encoded LMP1. Int J Cancer 53:856-862
43. Frisan T, Sjöberg J, Dolcetti R, Boiocchi M, De Re V, Carbone A, Brautbar C, Battat S, Biberfeld P, Eckman M, Öst Å, Christensson B, Sundström C, Björkholm M, Pisa P and Masucci MG (1995) Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's Disease. Blood 86:1493-1501
44. Knecht H, Bachmann E, Brousset P, Sandvej K, Nadal D, Bachmann F, Odematt BF, Delson G, Pallesen G (1993) Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's Disease and identical to those observed in nasopharingeal carcinoma. Blood 82:2937-2942
45. Hu LF, Zabarowsky ER, Chen F, Cao SL, Ernberg I, Klein G, Wimberg G (1991) Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. J Gen Virol 72:2399-2409